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Background: This study aimed to assess inter-observer variability between the original diagnostic reports and later
review by a specialist in breast pathology considering lobular neoplasias (LN), columnar cell lesions (CCL), atypical
ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS) of the breast.
Methods: A retrospective, observational, cross-sectional study was conducted. A total of 610 breast specimens that
had been formally sent for consultation and/or second opinions to the Breast Pathology Laboratory of Federal
University of Minas Gerais were analysed between January 2005 and December 2010. The inter-observer variability
between the original report and later review was compared regarding the diagnoses of LN, CCL, ADH, and DCIS.
Statistical analyses were conducted using the Kappa index.
Results: Weak correlations were observed for the diagnoses of columnar cell change (CCC; Kappa = 0.38),
columnar cell hyperplasia (CCH; Kappa = 0.32), while a moderate agreement (Kappa = 0.47) was observed for the
diagnoses of flat epithelial atypia (FEA). Good agreement was observed in the diagnoses of atypical lobular
hyperplasia (ALH; Kappa = 0.62) and lobular carcinoma in situ (LCIS; Kappa = 0.66). However, poor agreement was
observed for the diagnoses of pleomorphic LCIS (Kappa = 0.22). Moderate agreement was observed for the
diagnoses of ADH (Kappa = 0.44), low-grade DCIS (Kappa = 0.47), intermediate-grade DCIS (Kappa = 0.45), and DCIS
with microinvasion (Kappa = 0.56). Good agreement was observed between the diagnoses of high-grade DCIS
(Kappa = 0.68).
Conclusions: According to our data, the best diagnostic agreements were observed for high-grade DCIS, ALH,
and LCIS. CCL without atypia and pleomorphic LCIS had the worst agreement indices.
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Introdução: O objetivo do estudo foi avaliar a variabilidade interobservador entre os diagnósticos do laudo original
e após revisão por especialista em patologia mamária considerando as neoplasias lobulares (NL), lesões células
colunares (LCC), hiperplasia ductal atípica (HAD) e carcinoma ductal in situ (CDIS) em biopsias mamárias.
Métodos: Estudo retrospectivo, observacional, do tipo transversal. Um total de 610 casos de espécimes mamários
que foram enviados formalmente para consultoria e/ou segunda opinião ao Laboratório de Patologia Mamária da
Universidade Federal de Minas Gerais foram analisados entre janeiro de 2005 e dezembro de 2010. A variabilidade
interobservador entre o laudo original e o laudo de revisão foi comparada entre os diagnósticos de NL, LCC,
HDA e CDIS. A análise estatística foi realizada pelo índice de Kappa.
Resultados: Observamos uma concordância fraca para os diagnósticos de alterações de células colunares (ACC;
Kappa = 0,38), e hiperplasia de células colunares (HCC; Kappa = 0,32), enquanto uma concordância moderada
(Kappa = 0,47) foi observada para o diagnóstico de atipia epitelial plana (AEP). A concordância foi considerada boa
para os diagnósticos de hiperplasia lobular atípica (Kappa = 0,62) e carcinoma lobular in situ (CLIS; Kappa = 0,66).
Entretanto, a concordância foi considerado baixa para o diagnóstico de CLIS pleomórfico (Kappa = 0,22). Concordância
moderada foi observada para os diagnósticos de HLA (Kappa = 0,44), CDIS de baixo grau (Kappa = 0,47), CDIS de grau
intermediário (Kappa = 0,45) e CDIS microinvasor (Kappa = 0,56). Boa concordância foi observada para o diagnóstico de
CDIS de alto grau (Kappa = 0,68).
Conclusão: De acordo com nossos dados, as melhores concordâncias diagnósticas foram observadas entre CDIS de
alto grau, HLA e CLIS. As LCC sem atipias e o CLIS pleomórfico tiveram os piores índices de concordância.Background
Despite advances in the understanding of the molecular
biology of breast cancer progression and new molecular
markers, the histopathological analysis remains the most
widely used diagnostic method of precursor and intra-
ductal proliferative lesions of the breast [1].
Currently, increasing number of breast lesions are dis-
covered during the pre-clinical phase due to the more
widespread use of mammography screening and the in-
corporation of new imaging technologies for the diagnosis
of breast cancer. There has also been an increase in the
diagnosis of intraductal proliferative and precursor breast
lesions, which exhibit uncertain behaviour. These include
lobular neoplasia (LN), columnar cell lesions (CCL), atyp-
ical ductal hyperplasia (ADH), and ductal carcinoma in
situ (DCIS). The differential histologic diagnosis between
some of these lesions can be difficult and presents chal-
lenges to pathologists; especially those not specialized in
breast pathology [2,3].
Reproducibility studies are useful when evaluating the
applicability of histological criteria for the classification of
breast lesions and when determining the level of agree-
ment amongst pathologists regarding morphological diag-
noses. Studies conducted by our group have revealed
significant inter-observer variability between the diagnoses
made by general pathologists and those made by breast
pathology experts in the diagnosis for DCIS and ADH; this
discrepancy could have significant therapeutic implica-
tions [4,5]. Although there have been various studies on
the diagnostic agreement considering DCIS, few studieshave analysed the diagnostic agreement considering LN
and CCL [6,7].
Our study aimed to assess the frequency of detection
rate of precursor lesions and intraductal proliferative le-
sions, primarily CCL and LN, in breast biopsies sent for
consultation as well as the inter-observer variability in the
diagnoses made during the original report and a later re-
view by a specialist consultant in breast pathology.
Methods
A retrospective, observational, cross-sectional study
was conducted. Files from the Breast Pathology Labora-
tory at the School of Medicine of Federal University of
Minas Gerais (UFMG), Brazil, were reviewed between
January 2005 and December 2010, and 673 cases of
breast lesions were identified as having been formally
sent for consultation or second opinion. The analysed
data were obtained from the original pathologist reports
and from the consulting report conducted by a single
pathologist (HG) with an expertise on breast pathology.
A total of 63 cases were excluded from the analysis;
these cases did not have the original reports for com-
parison or they had insufficient and/or damaged mater-
ial that prevented the review.
Data were collected through the use of a structured
form, and the following items were analysed in both the
original report and the review: type of specimen, specialty
of the referring physician, and presence of intraductal pro-
liferative lesions (columnar cell lesions [CCL], ADH, and
DCIS) and the LN (atypical lobular hyperplasia [ALH],
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associated or not with invasive carcinoma.
The histological classification of LN originally reported
by Page et al. and adopted by the 2012 World Health
Organization (WHO) Classification of Breast Tumours was
used [1]. Lobular neoplasia refers to the entire spectrum of
atypical epithelial lesions originating in the terminal-duct
lobular unit (TDLU) and characterized by a proliferation of
generally small, non-cohesive cells. ALH is defined as a fill-
ing or expansion of less than 50% of the acini in one or
more lobular units by proliferating small, uniform cells.
LCIS was defined as a filling and distension of greater than
50% of the acini of a lobular unity and a loss of the residual
intracellular lumen [8,9]. The criteria used to diagnose
pleomorphic LCIS were those originally described by
Eusebi et al., which included the same architectural config-
uration as LCIS but with increased nuclear pleomorphism,
larger nucleoli, with or without comedo necrosis [10].
CCLs are a group of lesions of the terminal ductal-
lobular units that are characterized by variably enlarged
dilated acini lined by columnar epithelial cells without
cytological or architectural atipia [1]. Flat epithelial atypia
(FEA), the term adopted by the WHO Classification of
Breast Tumours, since 2003, refers to a neoplastic alter-
ation of the TDLUs characterized by replacement of the
native epithelial cells by one to several layers of a single
epithelial cell type showing low-grade (monomorphic)
cytological atypia [1,11]. These lesions differ from those
with sufficient architectural and cytological findings for a
differential diagnosis of ADH or DCIS. In the present
study, we used the diagnostic criteria proposed by Schnitt
and Vincent-Salomon, who previously suggested the clas-
sification of the FEA group into two groups, CCC and col-
umnar cell hyperplasia (CCH) with atypia according to the
number of layers of proliferating epithelial cells (Table 1)
[12,13].
ADH was defined as a proliferation of regularly dis-
tributed monomorphic cells to form regular, uniform,
and circular secondary lumens. These lesions are small,
and the cells have 2 partial ducts or “spaces” involved, and
are less than 2 mm in size. DCIS is characterised as an epi-
thelial proliferation of atypical cells with 2 complete
“spaces” or ducts involved or are more than 2 mm in over-
all size. The criteria of Elston and Ellis were used to diag-
nose DCIS with microinvasion [14], which are recognised
by predominant DCIS as well as the infiltration of neo-
plastic cells beyond the basal membrane of the unspecial-
ised or extralobular connective tissue up to 1 mm in size.
The histological grades (low, moderate, and high) of DCIS
were determined after considering the grade of nuclear
atypia as well as the presence and extension of necrosis ac-
cording to the criteria of Lagios [15]. Currently, the Breast
Pathology Laboratory uses the new WHO (2012) Classifi-
cation for Breast Tumours as a diagnostic reference [1].To tabulate the data, cases with more than one type of
breast lesion were classified according to the lesion with
the greatest risk or potential to develop into a carcinoma.
For LN, the risk classification was as follows: pleomorphic
LCIS > LCIS > ALH; for CCL: CCH atypia > CCC atypia >
CCH>CCC; and for DCIS: microinvasive DCIS > high-
grade DCIS > intermediate-grade DCIS > low-grade DCIS.
Cases of DCIS for which the grade had not been evaluated
during the original report or the review were classified as
unspecified (US).
The SPSS program (version 17.0; SPSS Inc., Chicago, IL,
USA) was used to analyse the inter-observer variability be-
tween the original diagnosis and the histopathological re-
view conducted by the consultant pathologist, using the
Kappa index. This index was interpreted according to the
following values proposed by Landis and Koch [16]: < 0.20
(bad); 0.21–0.40 (poor); 0.41–0.60 (moderate); 0.61–0.80
(good); and 0.81–1.00 (excellent). The significance level
(p) was defined as 0.05. This study was approved by the
Research Ethic’s Committee of the UFMG.
Results
A total of 610 cases of breast lesions that had been re-
ferred for second opinion and satisfied the inclusion cri-
teria were analysed; of these, 56.9% were breast specimens
from segmental mastectomies or quadrantectomies, 29.8%
from core-biopsies, 5.9% from mastectomies, and 7.4%
were other specimen types. The referring practitioner was
specialised in breast surgery in 60% of the cases, in oncol-
ogy in 5.2% of the cases, and in pathology in 4.1% of the
cases. Patients’ ages ranged from 13–94 years with a mean
age of 53.6 years (±13.3 years).
LN was present in 11.0% (67/610) of the original re-
ports and 11.8% (72/610) of the later reviews. Of 67
cases from the original reports, ALH was present in
25.4%, LCIS in 67.2%, and pleomorphic LCIS in 7.5%.
Of the 72 LN cases from the later reviews, ALH was
present in 30.6%, LCIS in 63.9%, and pleomorphic LCIS
in 5.6% (Table 2; Figure 1). There were good agreements
between the original reports and later reviews regarding
the diagnoses of ALH (Kappa index = 0.62; [p < 0,05])
and LCIS (Kappa index = 0.66; [p < 0,05]). However,
there was a poor agreement between the diagnoses of
pleomorphic LCIS (Kappa index = 0.22; [p < 0,05]).
CCL were present in 14.4% (88/610) of the original re-
ports and 25.1% (153/610) of the reviews. Of 88 cases
from the original reports, CCC were present in 64.8%,
CCH in 12.5%, CCC with atypia in 8.0%, and CCH with
atypia in 14.8% of the cases. Of the 153 cases from the
reviews, CCC were present in 74.5%, CCH in 9.8%, CCC
with atypia in 6.5%, and CCH with atypia in 9.2% of the
cases (Table 3; Figure 2). There were weak diagnostic
agreements between the original report and later review
for CCC (Kappa index = 0.38; [p < 0,05]), CCH (Kappa
Table 1 Diagnostic criteria for columnar cell lesions used in the present study













Architecture 1 or 2 cell layers Cell stratification greater than
2 layers, complex cellular
configurations are not present
1 or 2 cell layers Cellular stratification of more
than 2 layers, complex cell
configurations are not present
Cytology Columnar cells with ovoid
to elongated nuclei orientated
perpendicular to the basal
membrane; nucleolus absent
or inconspicuous.
Columnar cells with ovoid to
elongated nuclei orientated
perpendicular to the basal
membrane; “hobnail” cells
might appear with absent
or inconspicuous nuclei.
Cytological atypia present




(usually low-grade); the cells
resemble tubular carcinoma.
Mitoses are uncommon.










Might be present but





Might be present and
prominent.






Adapted from Schnitt and Vincent-Salomon [12], Fraser et al. [13], Tavassoli, & Devilee [11].
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index = 0.47; [p < 0,05]) between the diagnoses of FEA
(CCC with atypia and CCH with atypia).
ADH was present in 12.1% (74/610) of the original re-
ports and 8.4% (51/610) of the later reviews (Table 4;
Figure 2B and Figure 3). There was a moderate agreement
between the original reports and later reviews regarding the
diagnosis of ADH (Kappa index = 0.44; [p < 0,05]). Of the
74 cases of ADH present in the original reports, in 41.9%
(31/74) the reviewer confirmed the diagnosis of ADH. In
58.1% (43/74) cases the ADH was over-diagnosed, these,
58.1% (25/43) the reviewer downgrade diagnosis for usual
ductal hyperplasia, in 14.0% (6/43) the diagnosis was in-
creased to DCIS, and 27.8% (12/43) could not evaluate this
information only by the reports.
The DCIS frequencies in the original reports and later
reviews were 37.7% (230/610) and 39.0% (238/610), re-
spectively. Of 230 DCIS cases from the original reports,
low-grade DCIS was present in 25.6%, intermediate-grade
DCIS in 23.0%, high-grade DCIS in 39.1%, DCIS-US inTable 2 Diagnostic agreement between the original
report and later review of lobular neoplasia
LN report review
Original LN report Absent ALH LCIS Pleomorphic LCIS Total
Absent 521 10 11 1 543
ALH 7 8 2 0 17
LCIS 8 4 31 2 45
Pleomorphic LCIS 2 0 2 1 5
Total 538 22 46 4 610
LN: lobular neoplasia; ALH: atypical lobular hyperplasia; LCIS: lobular carcinoma
in situ.10.9%, and microinvasive DCIS in 1.3%. Of the 238 DCIS
cases encountered during later review, low-grade DCIS
was present in 26.5%, intermediate-grade DCIS in
20.6%, high-grade DCIS in 44.9%, DCIS-US in 5.9%, and
microinvasive DCIS in 2.1% (Table 5). Good diagnostic
agreement was observed between the original reports and
later reviews for high-grade DCIS (Kappa index = 0.68;
[p < 0,05]). However, moderate diagnostic agreement
was observed for low-grade DCIS (Kappa index = 0.47;Figure 1 Lobular neoplasia: this case was originally diagnosed as
lobular carcinoma in situ and considered atypical lobular
hyperplasia after review. Less than 50% of lobular units are involved
and expanded by uniform cells. (Hematoxylin and eosin; x200).
Table 3 Diagnostic agreement between the original









Absent 437 66 10 2 7 522
CCC 16 36 1 3 1 57
CCH 2 5 3 1 0 11
CCC with atypia 1 3 1 2 0 7
CCH with atypia 1 4 0 2 6 13
Total 457 114 15 10 14 610
CCL: columnar cell lesions; CCH: columnar cell hyperplasia; CCC: columnar
cell change.
Table 4 Diagnostic agreement between the original
diagnosis of atypical ductal hyperplasia and the
reviewer´s diagnosis
Reviewer´s diagnosis of ADH
Original diagnosis of ADH Absent ADH Total
Absent 516 20 536
ADH 43 31 74
Total 559 51 610
ADH: atypical ductal hyperplasia.
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[p < 0,05]), and microinvasive DCIS (Kappa index = 0.56;
[p < 0,05]).
Discussion
In this study, we analysed the LN, CCL, ADH and DCIS
diagnostic agreements and reproducibility between gen-
eral pathologists and a specialist pathologist with train-
ing and experience in breast pathology in cases received
in consultation for a second opinion.
The importance of LN morphological classification is at-
tributed to the Page group and collaborators, who corre-
lated lobular lesion extension with patient evolution. The
risks of developing invasive carcinomas were calculated as
4–5% for ALH and 8–11% for LCIS [8,9]. Eusebi et al. de-
scribed the pleomorphic variant of LCIS; this variant fea-
tures the same architectural arrangement as LCIS but
exhibits marked nuclear pleomorphism and abundant
cytoplasm, more evident nucleoli, and possible areas ofFigure 2 Diagnostic disagreements between the original
diagnosis of flat epithelial atypia and a low-grade ductal
carcinoma in situ and the reviewer´s diagnosis. A: Case originally
diagnosed as flat epithelial atypia and considered a columnar cell
change without atypia by the reviewer. (Hematoxylin and eosin; x400).
B: Case diagnosed by the reviewer as atypical ductal hyperplasia
(arrows) adjacent to columnar cell change without atypia (arrowheads)
and originally considered by the referral pathologist a low-grade ductal
carcinoma in situ. (Hematoxylin and eosin; x100).comedo necrosis and microcalcifications either with or
without apocrine characteristics [10]. Given the mor-
phological characteristics in association with the fact
that the imunohistochemical profile of pleomorphic
LCIS is more likely oestrogen receptor-negative and
HER-2-positive along with a higher Ki-67 proliferation
index that classic LCIS, these lesions have been corre-
lated with a more aggressive biological behavior than
that of classic LCIS; however, epidemiological studies to
prove this assumption are lacking [1,10]. Recently, mo-
lecular analyses of synchronous LCIS and both classic
ILC type and the pleomorphic variant of invasive lobu-
lar carcinoma demonstrated similarities in the genomic
profiles [17]. LCIS is considered both a risk factor and a
non-obligate precursor lesion for subsequent invasive
carcinomas in either breast, of either ductal or lobular
type, but only a minority of women actually develop in-
vasive breast cancer after a long-term follow up [1].Figure 3 Case originally diagnosed as atypical ductal hyperplasia
and as usual ductal hyperplasia after review. Note the epithelial
cells displaying a haphazard orientation, and the presence of slit-like
secondary lumina peripherally located. (Hematoxylin and eosin; x100).
Table 5 Diagnostic agreement between the original report and later review of DCIS
DCIS report review
Original DCIS report Absent LG DCIS IG DCIS HG DCIS US DCIS MIC DCIS Total
Absent 333 16 9 19 3 0 380
LG DCIS 16 32 9 0 2 0 59
IG DCIS 8 7 23 12 1 1 53
HG DCIS 6 3 5 72 2 2 90
US DCIS 8 5 3 3 6 0 25
MIC DCIS 0 0 0 1 0 2 3
Total 372 63 49 107 14 5 610
DCIS: ductal carcinoma in situ; LG DCIS: low-grade carcinoma in situ; IG DCIS: intermediate grade carcinoma in situ; HG DCIS: high-grade carcinoma in situ;
US DCIS: unspecified carcinoma in situ; MIC DCIS: microinvasive carcinoma in situ.
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served between the reports from generalist pathologists
and a breast pathology specialist regarding the diagnoses
of ALH (Kappa index = 0.62) and LCIS (Kappa index =
0.66). Our data are similar to those of Fitzgibbons, who
analysed the responses of 2,952 pathologists to clinical
cases from The College of American Pathologists Per-
formance Improvement Program in Surgical Pathology
[6]. That study analysed the agreement (%) regarding the
diagnosis of ALH; 58% of the pathologists correctly diag-
nosed ALH, whereas 17% diagnosed LCIS. When LN
(ALH and LCIS) cases were assessed together, the agree-
ment rate was 74%. However, there were other conflicting
diagnoses for these cases, including ADH (14%), DCIS
(1.4%), and usual ductal hyperplasia (10%) [6]. In fact, the
differential diagnosis of LN and intraductal proliferative le-
sions can be difficult, especially when concerning classic
LN versus low-grade solid DCIS, and pleomorphic LCIS
versus high-grade DCIS [2,18]. Despite the low number
of pleomorphic LCIS cases in our study, the inter-
observer agreement was poor (Kappa index = 0.22). The
immunophenotypic criteria of E-cadherin, β-catenin,
and p120-catenin expression in combination with the
careful identification of cytological and architectural al-
terations are useful tools in the morphological classifi-
cation of these lesions [18,19].
The correct diagnosis of LN cases will affect the treat-
ment options and counseling. Patients with LN are at risk
of developing invasive ipsilateral and contralateral breast
carcinomas. For this reason, most patients diagnosed with
LN are clinically monitored, and tamoxifen might be ad-
ministered as a prophylactic therapy against the develop-
ment of invasive carcinomas [20]. In very specific cases in
which there are other associated risk factors, a bilateral
prophylactic mastectomy might be offered [21]. The man-
agement of LN after core-biopsy diagnoses remains contro-
versial. Complete excision of the lesion is recommended in
patients who have been diagnosed with various forms of
LCIS; however, the current evidence does not support the
routine excision of conventional LCIS diagnosed via core-biopsy in cases with a clinical-radiological correlation and
in which suspected area on the image has been properly
sampled [1,2].
CCL and FEA are a group of breast lesions whose diag-
nostic criteria were defined only in recent years [12]. With
the widespread use of mammography screening, CCLs
have often been identified in breast biopsies and are
present in as many as half of the biopsies performed for
microcalcifications detected via mammography. Recent
studies have shown that flat epithelial atypia shares genetic
similarities with ADH, low-grade DCIS, and tubular car-
cinomas, suggesting that these lesions act as precursors of
invasive, low-grade carcinomas [22].
Despite advances in genetic studies of these lesions,
few studies have assessed the diagnostic reproducibility
of CCL amongst pathologists. In our study, we observed
weak diagnostic agreements regarding CCC and CCH
between generalist pathologists and a breast pathology
specialist. When we assessed FEA, the agreement was
moderate with better agreement for lesions with more
pronounced atypia. Our data differed from those of
O’Malley et al. [7], who observed excellent agreement
(Kappa index = 0.83) regarding the diagnoses of CCL
without atypia and FEA. The agreement was better
when detecting the absence of FEA (92.8%) than when
confirming its presence (90.4%). However, in contrast to
our study, the agreement was assessed in selected cases
and amongst pathologists experienced in breast path-
ology using images of the cases with pre-established
diagnostic criteria [7]. Haupt et al. analysed the diag-
nostic agreement regarding previously selected CCL
cases between residents and fellows both before and
after conducting a tutorial on the diagnostic criteria of
CCL. Before conducting the tutorial, the diagnostic
agreement of FEA was weak (Kappa index = 0.39); after
the training, there was a statistically significant increase
in the ability to recognise FEA (Kappa index = 0.60)
[23]. A similar study was conducted by Tan et al., who
analysed the diagnostic agreement of CCL amongst pa-
thologists from the same department after a tutorial;
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(Kappa index range = 0.44–0.71) between the group of
pathologists and the pathologist tutor [24].
The clinical importance of a correct diagnosis of FEA is
that these lesions often coexist alongside LN, ADH, low-
grade DCIS, and low-grade invasive carcinomas such as
tubular carcinomas [22,25]. In a recent meta-analysis,
Verschuur-Maes et al. analysed 24 studies that reported
the presence of carcinoma in situ after diagnosing CCL in
needle biopsies. DCIS underestimation rates of 1.5%, 9%,
and 20% were observed in cases of CCL without atypia,
CCL with atypia, and CCL associated with ADH, respect-
ively [26]. However, given the limitations of the studies and
the large variation in the time of follow-up after the initial
biopsy, the WHO Classification of Breast Tumours (2012)
notes that it remains uncertain whether the indication of
surgical excision is necessary after a diagnosis of FEA via
core needle biopsy. Radiological and pathological correla-
tions are recommended to determine the subsequent pro-
cedure [1]. Moreover, epidemiological studies such as that
conducted by Boulos et al. have revealed that CCL are as-
sociated with only a relative 1.55-fold risk of developing in-
vasive carcinomas in subsequent years; however, the risk
associated with these lesions is not entirely independent of
the risk associated with other concomitant proliferative
lesions [27].
ADH and DCIS comprise 10% and 15–20%, respectively,
of all breast lesions detected using mammography screen-
ing. The relative risk of developing invasive carcinoma
ranges from 4 to 5-fold among patients with a diagnosis of
ADH and from 8- to 10-fold among patients with DCIS
[1,28]. However, the histopathological diagnoses of these
intraductal proliferative lesions may be difficult, and the
inter- and intra-observer agreements between the patholo-
gists differ [5,29,30]. This diagnostic inconsistency could
be primarily a result of the morphological criteria used to
classify and appropriately select the diagnostic fields
[30,31]. The correct diagnosis and the differentiation be-
tween ADH and DCIS have repercussions for the treat-
ment of these lesions. When diagnosed via core biopsy,
ADH lesions must be completely removed to search for
DCIS in the excision specimen to avoid a missed detection
of an invasive component. In cases in which the diagnosis
of ADH was upheld after an extended biopsy, no further
treatment is necessary. However, given the greater risk
of progressing to an invasive carcinoma, DCIS has been
treated by complete excision of the lesion with free
margins, with complementary radiotherapy in cases for
which breast-conserving surgery has been performed,
and the use of tamoxifen as a prophylaxis against local
recurrence [32].
In our study, the diagnostic agreements between the ori-
ginal reports and later reviews were moderate for ADH
(Kappa index = 0.44), low-grade DCIS (Kappa index =0.47), intermediate-grade DCIS (Kappa index = 0.45), and
microinvasive DCIS (Kappa index = 0.56). Elston et al.
analysed the level of inter-observer agreement in the diag-
noses of ADH and DCIS amongst 23 pathologists who
used pre-defined diagnostic criteria. In this study, the
Kappa indices were considered poor (0.35) for ADH and
good (0.78) for DCIS. However, when DCIS cases were
stratified by histological grades, significant variations were
observed in the inter-observer diagnoses, as the Kappa in-
dices were 0.51 for low-grade DCIS, 0.19 for intermediate-
grade DCIS, and 0.41 for high-grade DCIS [31]. However,
in our study, we obtained a better agreement for the diag-
nosis of high-grade DCIS (Kappa index = 0.68). Similar
findings have been described by other authors that con-
ducted studies on the inter-observer variability with
regard to the nuclear grade of DCIS. Sneige et al. eval-
uated the inter-observer variability among six patholo-
gists who assessed 125 cases of DCIS and observed a
better diagnostic agreement for high-grade DCIS
[33,34]. The nuclear grade of DCIS is an important fac-
tor when determining the therapeutic approach be-
cause high nuclear-grade lesions are associated with a
poor prognosis and are often associated with local re-
currence and/or progression into invasive lesions, a
greater chance of metastasis, and greater required care
during local surgical procedures [4,28].
Various strategies have been used in an attempt to im-
prove the diagnoses of ADH and DCIS, including a re-
view of the diagnostic criteria and continuing education
programs [33]. Recently, Jain et al. revealed that the
agreement between nine pathologists regarding the diagno-
sis of ADH was poor (Kappa index = 0.34) and that an im-
munohistochemical analysis of cytokeratin (5, 14, 7 and 18)
and p63 protein expression significantly improved the level
of agreement among pathologists (Kappa index = 0.5) [30].
The influence of automated methods of interpretation [35]
and the use of telepathology and virtual slides has been
evaluated to improve the accuracy of diagnosis and as a
tool for education, quality control, and second opinion in
pathology [36,37].
As our study was retrospective, it includes some limita-
tions. Proliferative lesions may or may not be associated
with invasive carcinomas, a factor that might cause the gen-
eralist pathologist to underreport a case when faced with a
more aggressive diagnosis. Although our data were based
on pathological reports, upon assessing the aims of this
study, we believe that this methodology is similar to that
used in clinical practice.
Our study was the first to assess the diagnostic agree-
ment regarding CCL and LN in cases that were sent for
consultation according to reports by generalist patholo-
gists. Interestingly, in our series, a total of 60% of cases
were sent for consultation by breast surgeons and 5.2% of
cases were sent by oncologists. Only 4.1% of cases were
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mal requests for second opinions regarding precursor and
borderline breast lesions should be encouraged, especially
amongst general pathologists, with the aim of reducing er-
rors in diagnosis and thereby assuring appropriate thera-
peutic conduct and guaranteeing patient safety [4,5].
Conclusions
Our findings show a low degree of inter-observer diagnos-
tic agreement between generalist pathologists and a spe-
cialist in breast pathology with regard to CCL without
atypia and pleomorphic LCIS, moderate agreement for
FEA, ADH, and low-grade, intermediate, and microinva-
sive DCIS, and good agreement for high-grade DCIS,
ALH, and LCIS. We believe that the use of standardised
diagnostic criteria and specific training in breast pathology
might improve the reproducibility of these diagnoses,
thereby improving the reliability of the pathological re-
ports in the definition of the best therapeutic approach for
each patient.
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